FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034642806> ?p ?o ?g. }

• W2034642806 endingPage "909" @default.
• W2034642806 startingPage "909" @default.
• W2034642806 abstract "<h3>Objectives</h3>To compare topical interleukin 1 receptor antagonist (IL-1ra) to steroid treatment following photorefractive keratectomy (PRK) in rabbit eyes.<h3>Methods</h3>Our study is a randomized, investigator-masked study that was approved by the Institutional Animal Care and Use Committee. Following standard PRK, 48 eyes of 24 rabbits were divided into 5 arms: 4 treatment arms and 1 control arm. The right eye of each rabbit served as the treatment eye, and the left eye served as a control. Eyes in treatment arms were randomized to receive either fluorometholone, 0.1%, 4 times a day (Falcon, Fort Worth, Texas), or 2.5, 1.25, or 0.25 mg of IL-1ra 4 times a day. Control eyes received only moxifloxacin hydrochloride, 0.5% (Vigamox; Alcon, Fort Worth, Texas), and a solution of polyethylene glycol 400, 0.4%, and propylene glycol, 0.3% (Systane; Alcon), 4 times a day. Primary outcome measures included weekly evaluation of subjective haze formation and time to corneal reepithelization with clinic examinations, objective haze formation using Pentacam technology (Oculus, Lynnwood, Washington), as well as histological examination for haze thickness 7 weeks after PRK.<h3>Results</h3>There was no difference among treatment groups in time to reepithelization. The IL-1ra treatment groups showed a statistically significant reduction in haze formation (P < .001, determined by repeated-measures analysis of variance) on corneal evaluation using the Pentacam 3 weeks after PRK compared with the control group. This effect was comparable to that in the steroid treatment group. There was also a statistically significant effect of the treatment on subjective haze evaluation at weeks 4 and 5 (P < .05, determined by repeated-measures analysis of variance), but this effect lost statistical significance when the steroid group was excluded from the evaluation. In addition, there was no statistically significant difference in histologic evaluation of haze thickness among treatment groups (P = .997).<h3>Conclusion</h3>Further studies are needed to determine the efficacy and adverse effect profile of topical IL-1ra in human eyes.<h3>Clinical Relevance</h3>IL-1ra therapy may be an alternative to steroid treatment following PRK." @default.
• W2034642806 created "2016-06-24" @default.
• W2034642806 creator A5033432387 @default.
• W2034642806 creator A5034020449 @default.
• W2034642806 creator A5042154153 @default.
• W2034642806 creator A5063348880 @default.
• W2034642806 creator A5081534369 @default.
• W2034642806 date "2011-07-01" @default.
• W2034642806 modified "2023-09-23" @default.
• W2034642806 title "Effect of Topical Immunomodulatory Interleukin 1 Receptor Antagonist Therapy on Corneal Healing in New Zealand White Rabbits (<emph type=ital>Oryctolagus cunniculus</emph>) After Photorefractive Keratectomy" @default.
• W2034642806 cites W1571675602 @default.
• W2034642806 cites W1586272693 @default.
• W2034642806 cites W1936828909 @default.
• W2034642806 cites W1964947801 @default.
• W2034642806 cites W1965676394 @default.
• W2034642806 cites W1972882423 @default.
• W2034642806 cites W1981568232 @default.
• W2034642806 cites W1986204957 @default.
• W2034642806 cites W1990051204 @default.
• W2034642806 cites W1997895757 @default.
• W2034642806 cites W2001473459 @default.
• W2034642806 cites W2002257689 @default.
• W2034642806 cites W2004882711 @default.
• W2034642806 cites W2006227024 @default.
• W2034642806 cites W201100905 @default.
• W2034642806 cites W2012399470 @default.
• W2034642806 cites W2019061109 @default.
• W2034642806 cites W2021310874 @default.
• W2034642806 cites W2023771664 @default.
• W2034642806 cites W2030836332 @default.
• W2034642806 cites W2037323022 @default.
• W2034642806 cites W2038657395 @default.
• W2034642806 cites W2050589177 @default.
• W2034642806 cites W2053698739 @default.
• W2034642806 cites W2054101585 @default.
• W2034642806 cites W2065249066 @default.
• W2034642806 cites W2068103148 @default.
• W2034642806 cites W2073486354 @default.
• W2034642806 cites W2082603325 @default.
• W2034642806 cites W2092868206 @default.
• W2034642806 cites W2093956551 @default.
• W2034642806 cites W2114207233 @default.
• W2034642806 cites W2119350323 @default.
• W2034642806 cites W2144700815 @default.
• W2034642806 cites W2149528358 @default.
• W2034642806 cites W2332739634 @default.
• W2034642806 cites W2340799915 @default.
• W2034642806 cites W2370907612 @default.
• W2034642806 cites W2397769233 @default.
• W2034642806 cites W2417514779 @default.
• W2034642806 cites W2430272697 @default.
• W2034642806 cites W2431417703 @default.
• W2034642806 cites W2439675537 @default.
• W2034642806 cites W88741246 @default.
• W2034642806 doi "https://doi.org/10.1001/archophthalmol.2011.168" @default.
• W2034642806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21746982" @default.
• W2034642806 hasPublicationYear "2011" @default.
• W2034642806 type Work @default.
• W2034642806 sameAs 2034642806 @default.
• W2034642806 citedByCount "7" @default.
• W2034642806 countsByYear W20346428062014 @default.
• W2034642806 countsByYear W20346428062015 @default.
• W2034642806 countsByYear W20346428062018 @default.
• W2034642806 countsByYear W20346428062019 @default.
• W2034642806 countsByYear W20346428062021 @default.
• W2034642806 countsByYear W20346428062022 @default.
• W2034642806 crossrefType "journal-article" @default.
• W2034642806 hasAuthorship W2034642806A5033432387 @default.
• W2034642806 hasAuthorship W2034642806A5034020449 @default.
• W2034642806 hasAuthorship W2034642806A5042154153 @default.
• W2034642806 hasAuthorship W2034642806A5063348880 @default.
• W2034642806 hasAuthorship W2034642806A5081534369 @default.
• W2034642806 hasBestOaLocation W20346428061 @default.
• W2034642806 hasConcept C118487528 @default.
• W2034642806 hasConcept C2776882836 @default.
• W2034642806 hasConcept C2778257484 @default.
• W2034642806 hasConcept C2780603455 @default.
• W2034642806 hasConcept C2781135284 @default.
• W2034642806 hasConcept C71924100 @default.
• W2034642806 hasConceptScore W2034642806C118487528 @default.
• W2034642806 hasConceptScore W2034642806C2776882836 @default.
• W2034642806 hasConceptScore W2034642806C2778257484 @default.
• W2034642806 hasConceptScore W2034642806C2780603455 @default.
• W2034642806 hasConceptScore W2034642806C2781135284 @default.
• W2034642806 hasConceptScore W2034642806C71924100 @default.
• W2034642806 hasIssue "7" @default.
• W2034642806 hasLocation W20346428061 @default.
• W2034642806 hasLocation W20346428062 @default.
• W2034642806 hasOpenAccess W2034642806 @default.
• W2034642806 hasPrimaryLocation W20346428061 @default.
• W2034642806 hasRelatedWork W137818130 @default.
• W2034642806 hasRelatedWork W2032541745 @default.
• W2034642806 hasRelatedWork W2033417651 @default.
• W2034642806 hasRelatedWork W2052741930 @default.
• W2034642806 hasRelatedWork W2065249066 @default.
• W2034642806 hasRelatedWork W2245260622 @default.
• W2034642806 hasRelatedWork W2404889013 @default.
• W2034642806 hasRelatedWork W3043344165 @default.

• next